Clear Street raised the firm’s price target on Beam Therapeutics (BEAM) to $37 from $34 and keeps a Buy rating on the shares following the Q3 report. BEAM-103 has dosed the first patient in a healthy volunteer study while the next major catalyst for the shares being the interim update from BEAM-302 in early 2026, the analyst tells investors in a research note. Clear adds that Beam owns 17% of private company Orbital Therapeutics, which amounts to $255M in its recently announced takeout.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Cathie Wood Steps Up Bet on Bullish Stock (BLSH), Trims Stake in Palantir (PLTR) amid Strong Q3 Earnings
- Beam Therapeutics reports Q3 EPS ($1.10), consensus ($1.03)
- Promising Potential of BEAM-101 in Sickle Cell Treatment Justifies Buy Rating
- Cathie Wood’s ARK Investment buys 336K shares of Beam Therapeutics today
- EQT, Cummins, Beam, Chubb, Amphenol: Insider Sales Unveiled